Studies have described germline pathogenic mutations of HRR genes like BRCA2, CHEK1 and RAD51D in SCLC patients [39] and have investigated the potential benefit of PARP inhibitors in SCLC therapy [40]. The gene discussed is CHEK1; the disease is small cell lung carcinoma.